Silence Therapeutics ($SLN) Stock Hub 2026: Positive SANRECO Phase 2 Data, Q2 Results And The Upsized US$175 Million Offering

01Executive Summary

Silence Therapeutics is no longer a pre-readout, single-catalyst setup. The randomized SANRECO Phase 2 study produced a large controlled effect: 88% of divesiran-treated patients met the primary responder definition versus 19% on placebo, with p<0.0001. The responder definition was clinically concrete—no phlebotomy and haematocrit below 45% during weeks 18 through 36—rather than a biomarker-only endpoint.

The less frequent regimen also worked. Response was 93.8% every six weeks and 81.3% every twelve weeks. Mean phlebotomies were 0.2 with divesiran versus 2.1 with placebo, while haematocrit, ferritin and patient-reported MPN-SAF Total Symptom Score moved in the expected direction. The company reported no new safety findings; injection-site reactions were infrequent and self-limiting, and two investigator-reported anaemia cases were Grade 1.

The remaining clinical uncertainty is different, not gone. Forty-eight patients cannot establish uncommon safety events, long-term durability, Phase 3 effect size or commercial uptake. Full results are still intended for a medical congress, and all participants are now in a three-year blinded/open-label extension. Silence plans a Phase 3 start in the first half of 2027 using the Q12W regimen versus placebo.

Q2 liquidity was US$72.1 million, Q2 R&D was US$9.1 million and net loss was US$12.3 million. One day after the data, Silence priced an upsized US$175 million public offering of 12,962,963 ADS at US$13.50. That converts a previously constrained balance sheet into a Phase 3-capable one, at the price of substantial ownership dilution.

02What The Company Actually Is Today

Silence Therapeutics plc is a London-based clinical-stage siRNA company listed on Nasdaq through American Depositary Shares. Its mRNAi GOLD chemistry is designed to silence liver-expressed disease targets through infrequent subcutaneous dosing. After SANRECO, the company is best understood as a Phase 3 haematology developer with two cardiovascular partnering options rather than as a broad platform story.

There is still no product revenue. Q2 revenue was zero and first-half collaboration revenue was US$0.422 million. The key economic assets are the probability-adjusted value of divesiran, potential partnering terms for zerlasiran, the post-offering cash balance and the cost required to reach the next clinical proof.

03Divesiran And The Positive SANRECO Readout

Polycythaemia vera is a myeloproliferative neoplasm in which excess red-cell production requires many patients to undergo repeated therapeutic phlebotomy to keep haematocrit below 45%. Divesiran silences TMPRSS6, raises hepcidin and restricts iron availability for erythropoiesis. The intended clinical benefit is fewer procedures, better iron stores and lower symptom burden without creating clinically important anaemia.

The central commercial result is the Q12W arm. An every-twelve-week injection that preserves haematocrit control and reduces phlebotomy burden would be easier to differentiate than a more frequent regimen. The numerical gap between Q6W and Q12W still matters, however: Phase 3 must show that convenience does not trade away too much efficacy.

The next evidence layers are full congress-level data, the three-year extension, regulatory feedback and the Phase 3 protocol. Important details include baseline phlebotomy burden, confidence intervals, subgroup consistency, duration after the last dose, anaemia thresholds, discontinuations and how rescue phlebotomy is handled.

04The Phase 1 Evidence Behind The Phase 2

On June 11, 2026 Silence presented follow-up Phase 1 data at the EHA Congress. These are the numbers the Phase 2 has to reproduce at larger scale, and they are worth stating precisely because most secondary coverage rounds them.

The reduction from 80 phlebotomies to five is the headline, and it is a large effect. The median time to first phlebotomy of 287 days is arguably the more useful number, because it describes durability rather than suppression: nine and a half months without a procedure, in a disease where the alternative is a recurring appointment.

The caveats are the ordinary ones for a Phase 1. Twenty-one patients is a small sample, the design is open-label rather than controlled, and the pre-treatment period is a historical comparison within the same patients rather than a randomised control arm. Effects of that size in a small open-label study regularly shrink when a control group is introduced. They do not always shrink to nothing, which is why the Phase 2 exists.

05Zerlasiran: Phase 3-Ready And Unpartnered

Zerlasiran is an siRNA targeting lipoprotein(a), a genetically determined lipid particle that is an independent cardiovascular risk factor and for which no approved lowering therapy exists. The commercial logic is obvious and the competitive field is not empty: several large companies are running outcomes trials in the same target.

Silence describes the asset as Phase 3-ready and states that it is seeking a development partner. That sentence carries the whole financial argument of the company. A cardiovascular outcomes trial in an unapproved target is a multi-year, multi-hundred-million-dollar programme. Even after the offering, a cardiovascular outcomes program would compete directly with divesiran Phase 3 for capital; a development partner remains the economically disciplined path.

The consequence shows up directly in the income statement. Research spending fell 56% year on year in the first quarter of 2026, and the company attributed the decline specifically to the completion of zerlasiran Phase 3 readiness work during 2025. The programme is finished as a cost line and has not yet started as a revenue line.

06SLN312 And The AstraZeneca Return

On March 4, 2026 AstraZeneca decided not to develop SLN312 beyond Phase 1, and Silence regained full global rights to the asset. Phase 1 data were accepted for a late-breaking oral presentation at the EAS Congress held May 24-27, 2026.

There are two readings of this event and both are legitimate. The negative reading is straightforward: a large pharmaceutical partner examined the Phase 1 data and chose not to continue, which is information about the asset even when no reason is disclosed. The positive reading is that a returned asset with presentable Phase 1 data costs Silence nothing to hold and can be re-partnered or shelved at will.

What it is not is a source of near-term value. SLN312 is a third asset in a company that cannot fund its second. It belongs in the pipeline table and not in the investment case.

07Q2 2026 Financial Results

Silence reported Q2 results on August 10, the same day as the SANRECO topline. The cost base remained below the prior year as zerlasiran Phase 3-readiness spending stayed off the income statement.

First-half revenue was US$0.422 million, confirming that collaboration income is not an operating base. The fall in R&D and net loss reflects completed development work and the timing of programs; it should not be extrapolated after a Phase 3 start. The company also highlighted preclinical SLN365 and SLN098 as potential 2027 IND candidates, which could add spend alongside divesiran.

The per-share figure is reported on ordinary shares. Because one ADS represents three ordinary shares, readers should not compare the US$0.09 ordinary-share loss directly with the Nasdaq ADS price.

08Cash, Runway And Post-Offering Liquidity

Cash, cash equivalents and short-term investments were US$72.1 million at June 30. The company continued to state runway into 2028 under the existing plan. The August offering changes the more relevant question from survival to execution capacity.

Adding the US$175 million base gross proceeds to Q2 liquidity gives approximately US$247.1 million before underwriting discounts, commissions, offering expenses and cash used after June 30. If the underwriters exercise their option in full, gross proceeds rise to about US$201.25 million and the same simple pro forma reaches approximately US$273.35 million. These are derived gross figures, not company guidance or reported pro forma cash.

The enlarged balance sheet should fund Phase 3 preparation from a position of strength, but it is not free capital. A multicentre registrational trial, long-term extension, manufacturing, regulatory work and two possible preclinical INDs can lift R&D well above the recent US$9.1 million quarterly level. The relevant monitoring metric becomes cash spent per value-creating milestone.

09Capital Structure, ADS Ratio And Offering Dilution

Silence is a UK plc represented on Nasdaq by ADSs, with three ordinary shares per ADS. At June 30 it had 141,739,180 ordinary shares, equivalent to approximately 47,246,393 ADS before the offering.

The two dilution percentages answer different questions. Share-count expansion compares newly issued ADS with the pre-deal base. Ownership dilution measures the reduction in an existing holder’s percentage of the larger post-deal company, assuming no participation. Neither includes employee awards or later issuance.

The offering was priced, upsized and expected to close August 13, subject to customary conditions. Jefferies, Morgan Stanley, Cantor and William Blair are the bookrunners, and the underwriters have a 30-day option for 1,944,444 additional ADS.

10Analysts And Market Data

Market data below combine the last Stocktwits print of August 7, 2026 with the Stock Analysis statistics page, which was showing data to August 1, 2026 at the time of writing. Where the two differ, both are given.

Analyst coverage

Seven analysts cover the stock and their published targets do not agree with each other in any meaningful sense. This is the widest dispersion in the Merlintrader coverage series.

A high target that is nearly nineteen times the low target is not a consensus with error bars around it. It is two incompatible views of the same company: one in which divesiran works and zerlasiran finds a partner, and one in which neither happens and the equity is worth its cash. An average of US$29.17 derived from that distribution is an arithmetic artefact and should not be read as a central expectation.

It is also worth noting the timing. The Goldman Sachs Sell rating at US$4 is dated July 27, 2026, the most recent of the published targets and the one set closest to the August readout.

11Retail Sentiment

As of August 9, 2026 the Stocktwits $SLN stream showed 486 watchers, and no sentiment series was returned, meaning there were too few sentiment-tagged messages in the period to compute a bullish or bearish percentage.

That is roughly three times the following of the other name added to this coverage series this week, and still very small in absolute terms. The pre-readout absence of a sentiment series showed limited U.S. retail participation despite the approaching catalyst. That historical snapshot is retained as a record of positioning before the August 10 data, not as a current directional signal.

The practical implication is about mechanics rather than direction. Thin retail participation and an ADS structure mean the price reaction to the data is more likely to be a single repricing gap than the multi-day retail-driven run that often accompanies a small-cap catalyst.

12What Bulls See

Randomized proof, not a historical comparison. SANRECO’s 88% versus 19% responder result and p<0.0001 materially strengthen the Phase 1 signal.

Both schedules worked. The 81.3% response on Q12W supports a commercially attractive quarterly regimen while Q6W reached 93.8%.

Benefit across multiple dimensions. Phlebotomies, haematocrit, ferritin and patient-reported symptoms all moved in the intended direction.

No new safety finding in Phase 2. Injection reactions were described as infrequent and self-limiting, with only two investigator-reported Grade 1 anaemia cases.

Phase 3 financing risk is lower. Approximately US$175 million of base gross proceeds arrives after positive data and can fund development from strength.

Additional optionality remains. Zerlasiran is Phase 3-ready and unpartnered, while SLN365 and SLN098 could enter the clinic in 2027.

13What Bears See

The study is still small. Forty-eight patients cannot define uncommon safety, long-term adherence or a registrational effect size.

Q12W was numerically below Q6W. The convenience advantage is valuable only if Phase 3 preserves sufficient efficacy.

The offering is materially dilutive. Base share-count expansion is about 27.4%; full option exercise would lift it to about 31.5% before other equity awards.

Phase 3 spend will reverse the lean cost base. Recent R&D reflects completed programs, not the cost of a registrational haematology study plus preclinical expansion.

Zerlasiran remains unpartnered and SLN312 was returned. Positive divesiran data do not validate every platform asset or guarantee attractive licensing economics.

Full SANRECO detail is pending. Confidence intervals, subgroup consistency, detailed safety and durability will matter when presented at a medical meeting and in the extension.

14Scenario Framework

These scenarios organize the post-SANRECO path; they are not forecasts, price targets or recommendations.

The middle path is a viable Phase 3 program with a real effect but more modest differentiation than the topline implies. In that case the value debate moves to trial design, time to registration, commercial positioning and disciplined use of the offering proceeds.

15Bottom Line

Silence delivered the two events that the pre-readout hub could not assume: a positive controlled Phase 2 and a financing large enough to support the next stage. The 88% versus 19% responder rate, 0.2 versus 2.1 mean phlebotomies and useful Q12W activity make divesiran a credible Phase 3 asset rather than an interesting Phase 1 signal.

The cost is dilution. The base offering expands the pre-deal ADS equivalent by about 27.4%, or reduces an existing holder’s percentage ownership by about 21.5% before other securities. In exchange, simple gross pro forma liquidity rises to roughly US$247 million before fees and post-quarter burn. That trade is rational if Phase 3 converts the clinical signal into durable, registrational and commercially differentiated evidence.

The disciplined classification is now positive proof with execution still outstanding. The decisive checkpoints are detailed SANRECO data, long-term safety and anaemia, regulatory agreement, the 1H27 Phase 3 start, cash deployment and any zerlasiran partnership. This is an educational framework, not a recommendation to buy, sell or hold $SLN.